The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity			
Olk (Eller ID N	Previous	Пы	Falls T
CIK (Filer ID Number)	Names	None	Entity Type
<u>0001516551</u>	Emerald Bios	cience, Inc.	X Corporation
Name of Issuer	Nemus Biosci		Limited Partnership
Skye Bioscience, Inc.		RD LOGISTICS, INC.	Limited Liability Company
Jurisdiction of Incorporation/Organiza	tion Load Guard T	ransportation, Inc.	
NEVADA			General Partnership
Year of Incorporation/Organization			Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Specify Ye	ear)		
Yet to Be Formed			
2. Principal Place of Business and	Contact Information		
Name of Issuer			
Skye Bioscience, Inc.			
Street Address 1		Street Address 2	
11250 EL CAMINO REAL, SUITE 100			
	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SAN DIEGO	CALIFORNIA	92130	(858) 410-0266
3. Related Persons			
Last Name	First Name		Middle Name
Dhillon	Punit		
Street Address 1	Street Address 2		
1250 El Camino Real	Suite 100		
City	State/Province/Co	untry	ZIP/PostalCode
San Diego	CALIFORNIA		92130
Relationship: \overline{X} Executive Officer \overline{X} I	Director Promoter		
Clarification of Response (if Necessar	y):		
Chief Executive Officer, Chairman and D	irector		
Last Name	First Name		Middle Name
Arsenault	Kaitlyn		
Street Address 1	Street Address 2		
11250 El Camino Real	Suite 100		
City	State/Province/Co	untry	ZIP/PostalCode
San Diego	CALIFORNIA		92130
Relationship: X Executive Officer C			
Clarification of Response (if Necessar	y):		
Chief Financial Officer			
Last Name	First Name		Middle Name
Dalesandro	Margaret		
Street Address 1	Street Address 2		
11250 El Camino Real	Suite 100		
City	State/Province/Co	untry	ZIP/PostalCode
San Diego	CALIFORNIA		92130

Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessal	ry):		
Last Name	First Name	Middle Name	
Charych	Deborah		
Street Address 1	Street Address 2		
11250 El Camino Real	Suite 100		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92130	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessar	ry):		
Last Name	First Name	Middle Name	
Tyle	Praveen		
Street Address 1	Street Address 2		
11250 El Camino Real	Suite 100		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92130	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessar	ry):		
Last Name	First Name	Middle Name	
Ward	Keith		
Street Address 1	Street Address 2		
11250 El Camino Real	Suite 100		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92130	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessal	ry):		
Last Name	First Name	Middle Name	
Schwab	Andrew	Wilder Name	
Street Address 1	Street Address 2		
11250 El Camino Real	Suite 100		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92130	
Relationship: Executive Officer X		72130	
Clarification of Response (if Necessal			
		APT ULL AL	
Last Name	First Name	Middle Name	
Grayson	Paul		
Street Address 1	Street Address 2		
11250 El Camino Real	Suite 100	710/04-10-4-	
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92130	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessal	ry):		
Last Name	First Name	Middle Name	
Jenkins	Annalisa		
Street Address 1	Street Address 2		
12250 El Camino Real	Suite 100		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92130	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessar	ry):		

4. Industry Group

Agriculture	Health Care	Retailin	ng	
Banking & Financial Services	X Biotechnology	Restau	irante	
Commercial Banking	Health Insurance	Techno		
Insurance	Hospitals & Physicians	_	nputers	
Investing	Pharmaceuticals			
Investment Banking		Tele	ecommunications	
Pooled Investment Fund	Other Health Care	Othe	er Technology	
Is the issuer registered as an investment company under the Investment Company	Manufacturing Real Estate	Travel Airlir	nes & Airports	
Act of 1940?	Commercial	П	ging & Conventions	
Yes No	Construction		-	
Other Banking & Financial Services	REITS & Finance	Toui	rism & Travel Services	
Business Services		Othe	er Travel	
Energy	Residential	Other		
Coal Mining	Other Real Estate			
Electric Utilities				
Energy Conservation				
Environmental Services				
Oil & Gas				
Other Energy				
5. Issuer Size				
Revenue Range OR	Aggregate Net A	Asset Value	Range	
No Revenues	No Aggregate	e Net Asset '	Value	
\$1 - \$1,000,000	\$1 - \$5,000,0	00		
\$1,000,001 - \$5,000,000	\$5,000,001 -	\$25,000,000	0	
\$5,000,001 - \$25,000,000	\$25,000,001	- \$50,000,00	00	
\$25,000,001 - \$100,000,000	\$50,000,001	- \$100,000,0	000	
Over \$100,000,000	Over \$100,00	00,000		
X Decline to Disclose	Decline to Dis	sclose		
Not Applicable	Not Applicable	е		
6. Federal Exemption(s) and Exclusion(s)	Claimed (select all that app	lv)		
<u> </u>		-3,		
	Investmer	nt Company	Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3((c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(i)	Section 3((c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(ii)				
Rule 504 (b)(1)(iii)	Section 3(Section 3(c)(11)	
X Rule 506(b)	Section 3((c)(4)	Section 3(c)(12)	
Rule 506(c)	Section 3((c)(5)	Section 3(c)(13)	
Securities Act Section 4(a)(5)	Section 3((c)(6)	Section 3(c)(14)	
	Section 3(L	
		(=)(1)		
7. Type of Filing				
X New Notice Date of First Sale 2024-03-1	3 First Sale Yet to Occur			
Amendment				
8. Duration of Offering				
Does the Issuer intend this offering to last m	nore than one year?	X No		

9. Type(s) of Securities Offered (select all that apply)		
X Equity	Pooled Investment Fund Interests	
Debt	Tenant-in-Common Securities	
片	봄	
Option, Warrant or Other Right to Acquire Another Security	☐ Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, Warrant or Other I Acquire Security	Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combination to or exchange offer?	transaction, such as a merger, acquisition Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USD		
12. Sales Compensation		
Recipient	Recipient CRD Number None	
Piper Sandler & Co	665	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number \overline{X} None	
None	None	
Street Address 1	Street Address 2	
800 Nicollet Mall	Suite 900	
City	State/Province/Country	ZIP/Postal Code
Minneapolis	MINNESOTA	55402
State(s) of Solicitation (select all that apply) Check "All States" or check individual States X All States	Foreign/non-US	
Recipient	Recipient CRD Number None	
Oppenheimer & Co. Inc.	249	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None	
None	None	
Street Address 1	Street Address 2	
85 Broad Street	22nd and 24th Floors	
City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10004
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$40,000,000 USD or Indefinite		
Total Amount Sold \$40,000,000 USD		
. , ,		
Total Remaining to be Sold \$0 USD or Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or may be sold to personauch non-accredited investors who already have invested in the offer Regardless of whether securities in the offering have been or may be total number of investors who already have invested in the offering:	fering. be sold to persons who do not qualify as accredited investors,	
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders fees check the box next to the amount.	expenses, if any. If the amount of an expenditure is not known	, provide an estimate and
Sales Commissions \$2,400,000 USD Estimate		
Finders' Fees \$0 USD Estimate		

		ceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named	d as
executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amoun	

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the
 accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Skye Bioscience, Inc.	/s/ Kaitlyn Arsenault	Kaitlyn Arsenault	Chief Financial Officer	2024-03-25

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.